Top regulatory partners for cell and gene therapy submissions (ATMP regulation): why most companies fail before submission

You’re developing a breakthrough therapy with real clinical potential – but as you move closer to submission, progress slows, requirements multiply, and uncertainty starts to build. This is exactly why companies begin searching for top regulatory partners for cell and gene therapy submissions – not out of preference, but out of necessity. The core issue is almost always the same: Advanced Therapy Medicinal Products regulation (ATMP regulation) is far more complex than expected, governed in the EU by a dedicated framework (Regulation 1394/2007) that requires centralised approval, strict classification, and full alignment across quality, clinical, and safety data . Without a clear strategy from the beginning, even strong science becomes difficult to translate into an approvable dossier. And that’s where the real risk emerges – delays, rework, and regulatory objections that could have been avoided months earlier. By the time gaps appear, timelines are already compromised and costs are rising. What you need at that point is not more fragmented support, but a partner who understands how to navigate ATMP regulation end-to-end and can translate regulatory complexity into a structured, submission-ready pathway before it’s too late.

Why ATMP regulation makes finding “top regulatory partners for cell and gene therapy submissions” critical

For companies developing advanced therapies, the search for top regulatory partners for cell and gene therapy submissions usually starts when complexity begins to slow everything down – but the real issue starts much earlier, with how ATMP regulation fundamentally reshapes the entire development pathway. In the EU, gene and cell therapies fall under a dedicated legal framework (Regulation 1394/2007), requiring centralised marketing authorisation and evaluation by specialised EMA committees such as CAT (The Committee for Advanced Therapies) and CHMP (The Committee for Medicinal Products for Human Use) . This means your product is not just assessed as a medicine, but as a highly specialised therapy where quality, clinical data, and long-term safety must be fully aligned from the beginning.

The problem is that most companies approach this too late. They treat regulatory as a final submission step rather than as a driver of development. But ATMP requirements are built on dozens of specific guidelines covering quality, non-clinical, and clinical aspects – many of which are unique and do not overlap with traditional biologics . This creates a situation where even small gaps – misaligned data, unclear classification, or inconsistent documentation – can lead to significant delays during evaluation.

That’s why choosing the right partner is not a “nice to have” – it directly impacts whether your product reaches approval or gets stuck in repeated cycles of questions, objections, and rework.

How Billev Pharma East solves ATMP regulation challenges end-to-end

If ATMP regulation is what creates the problem, then execution across the entire lifecycle is what solves it – and that’s exactly where most companies fail. They rely on fragmented vendors, disconnected internal teams, or consultants who define strategy but don’t stay accountable for delivery. The result is predictable: misalignment between development, GMP, clinical data, and submission, which ultimately delays or blocks approval under the centralised EMA procedure required for ATMPs .

At Billev Pharma East, we take a fundamentally different approach. We act as one integrated partner across development, GMP, and lifecycle compliance, ensuring that your product is not just planned correctly – but executed in a way that is fully aligned with regulatory expectations from day one .

Our strength lies in connecting every critical component of your ATMP pathway:

• Preclinical and clinical development aligned with regulatory strategy from the start
• Regulatory / CMC execution, including dossier preparation and staretegic positioning for scientific advice
• Manufacturing and GMP systems tailored specifically to ATMP requirements
• Medical consultancy and pharmacovigilance, ensuring long-term safety and a robust benefit-risk profile
• End-to-end patient journey optimisation, especially critical for complex and personalised therapies

What makes the difference is not just the breadth of services – but how they are integrated. ATMPs require a fully connected approach because regulatory expectations span classification, quality, clinical evidence, and long-term follow-up. When these elements are managed separately, gaps appear. When they are managed together, the pathaway to approval becomes significantly more predictable.

So when companies search for top regulatory partners for cell and gene therapy submissions, the real answer is not a vendor who supports one step – it’s a partner who can take ownership of the entire pathway and guide your product from early development to patient impact without unnecessary delays.

Advanced Therapies Congress London: why real industry presence matters in ATMP regulation

When evaluating top regulatory partners for cell and gene therapy submissions, one factor is often overlooked: real presence in the ATMP ecosystem. Not just theoretical knowledge – but active involvement in the environments where the industry is actively evolving.

This is especially important in the context of ATMP regulation, where expectations are continuously shaped by emerging technologies, manufacturing challenges, and ongoing regulatory dialogue across the global community.

One of the key meeting points for this ecosystem was the Advanced Therapies Congress by Terrapinn, held in London at ExCeL. As Europe’s largest commercial cell and gene therapy conference and exhibition, it brought together more than 3,000 global executives, over 300 speakers, and stakeholders across the entire ATMP value chain, including biotech, pharma, regulators, and innovators .

At Billev Pharma East, we believe that being part of this environment is essential – not optional. Our team, represented by Katja Pečjak Reven, Maša Voler, Eva Trošt Lah, and Staša Taferner, was present in London with an exhibition stand, engaging directly with industry leaders, partners, and decision-makers across the ATMP landscape. Our objective was not only visibility, but active participation: to understand current challenges companies face in development and submission, to stay aligned with evolving regulatory expectations, and to continuously refine how we approach ATMP regulation in practice.

This kind of presence ensures something critical – continuous alignment with where the industry is going, not where it was. Because in ATMP development, regulatory success is not built on static knowledge or outdated assumptions, but on real-time insight into how expectations, technologies, and regulatory thinking continue to evolve.

And when choosing between top regulatory partners for cell and gene therapy submissions, that level of engagement is what separates theoretical expertise from a partner who truly understands the reality of bringing advanced therapies to approval.

What to look for in top regulatory partners for cell and gene therapy submissions

When companies evaluate top regulatory partners for cell and gene therapy submissions, they often focus on reputation or size – but that’s rarely what determines success under ATMP regulation. The real difference lies in whether a partner can actively reduce regulatory risk across the entire pathway.

First, deep ATMP-specific expertise is non-negotiable. These products are governed by a standalone regulatory framework (Regulation 1394/2007), with dedicated EMA evaluation and specialised committees such as CAT assessing quality, safety, and efficacy. This means your partner must understand nuances that simply don’t exist in traditional pharmaceuticals – like classification borderline cases, gene therapy-specific guidelines, and long-term follow-up requirements.

Second, early-stage involvement is critical. The EMA even provides formal classification procedures to clarify whether your product qualifies as an ATMP – highlighting how common and costly early misclassification can be.. A strong partner ensures these decisions are made early, not corrected later.

Third, integration matters more than specialization. ATMP submissions require alignment across CMC, clinical development, and pharmacovigilance. With over 100+ guidance documents specific to ATMPs, fragmentation can quickly lead to inconsistencies and regulatory objections .

Finally, ownership and scalability define the best partners. As your product progresses, regulatory complexity increases – not decreases. If your partner cannot scale with your programme, you will eventually outgrow them.

In reality, the “top” partner is not the one with the biggest name—but the one who can take full responsibility for getting your product approved.

“top regulatory partners for cell and gene therapy submissions” – how to make the right choice

Searching for top regulatory partners for cell and gene therapy submissions is ultimately a high-stakes decision. Under ATMP regulation, your partner doesn’t just influence your submission – they influence your timeline, your funding milestones, and your probability of approval.

So how do you make the right choice?

Start by asking a simple question: Can this partner deliver beyond advice? Many consultancies define strategy, but leave execution to your internal team. In ATMP development, that gap is where delays happen. EMA guidance clearly emphasises the importance of structured regulatory support throughout development – from manufacturing to clinical and post-authorisation planning.

Next, evaluate how they handle complexity. ATMPs require a risk-based approach, tailored to each product’s characteristics and lifecycle. This includes long-term safety monitoring and post-authorisation commitments, which must be planned early – not added at the end.

Finally, look for partners who think in lifecycle terms. The best outcomes come from teams that understand your product from early science through commercialisation – not just submission. Because at this level, choosing the wrong partner doesn’t just slow you down.

It can determine whether your therapy ever reaches patients.

Make the right decision when choosing top regulatory partners for cell and gene therapy submissions

Choosing between top regulatory partners for cell and gene therapy submissions is not just a procurement decision – it is a strategic decision that directly impacts your probability of approval under ATMP regulation. In the EU, every ATMP must go through a centralised procedure, meaning a single application, a single scientific evaluation by the EMA, and one decision valid across all Member States . This level of scrutiny leaves no room for misalignment, late corrections, or fragmented responsibility.

That’s why the most important question is not who looks strongest on paper, but who can actually deliver a complete, submission-ready pathway. The right partner ensures that classification, development, CMC, and long-term safety planning are aligned from the beginning – because under ATMP requirements, these elements are assessed together, not separately. If they are disconnected, regulators will identify gaps quickly, leading to questions, delays, and potential objections or even rejection.

A strong partner reduces this risk by structuring your programme early, anticipating regulatory expectations, and maintaining consistency across the entire lifecycle – from early development to post-authorisation commitments.

Because in the end, success in ATMP regulation is not about preparing documents – it’s about making the right strategic decisions early in development. And that choice is the partner who can tranlsate complexity into a clear, predictable path to approval.

Sources: 1 – European Medicines Agency. (n.d.). Advanced therapy medicinal products: Overview, 2 – European Medicines Agency. (n.d.). Legal framework: Advanced therapies, 3 – European Medicines Agency. (n.d.). Guidelines relevant for advanced therapy medicinal products, 4 – European Medicines Agency. (n.d.). Advanced therapy classification, 5 – European Medicines Agency. (n.d.). Committee for Advanced Therapies (CAT), 6 – European Medicines Agency. (2025). Guideline on quality, non-clinical and clinical requirements for investigational ATMPs, 7 – PharmaRegulatory.in. (2025). EU ATMP regulations explained: Complete guide to EMA and CAT framework.